Aclaris Therapeutics (NASDAQ:ACRS) Trading 9.1% Higher

Aclaris Therapeutics Inc (NASDAQ:ACRS)’s share price traded up 9.1% during mid-day trading on Friday . The stock traded as high as $0.95 and last traded at $0.87, 2,737,964 shares traded hands during mid-day trading. An increase of 272% from the average session volume of 736,442 shares. The stock had previously closed at $0.80.

Several research analysts have recently issued reports on the company. BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $5.00 target price (down from $24.00) on shares of Aclaris Therapeutics in a report on Friday, August 9th. Leerink Swann cut Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, June 27th. ValuEngine upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Svb Leerink cut Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, June 27th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Aclaris Therapeutics has a consensus rating of “Hold” and a consensus target price of $14.94.

The company has a fifty day moving average of $1.73 and a 200 day moving average of $4.85. The firm has a market capitalization of $36.12 million, a P/E ratio of -0.22 and a beta of 0.74. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.23 and a quick ratio of 4.30.



Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.77) by $0.05. Aclaris Therapeutics had a negative return on equity of 81.40% and a negative net margin of 979.65%. The business had revenue of $5.87 million for the quarter, compared to analysts’ expectations of $5.77 million. On average, sell-side analysts forecast that Aclaris Therapeutics Inc will post -2.62 EPS for the current year.

In other Aclaris Therapeutics news, major shareholder James E. Flynn sold 699,475 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $2.69, for a total transaction of $1,881,587.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder James E. Flynn sold 454,261 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $4.59, for a total value of $2,085,057.99. The disclosure for this sale can be found here. Insiders sold 1,493,273 shares of company stock worth $5,535,307 over the last quarter. 14.80% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of ACRS. Aperio Group LLC bought a new position in shares of Aclaris Therapeutics during the 2nd quarter worth approximately $33,000. BNP Paribas Arbitrage SA boosted its holdings in shares of Aclaris Therapeutics by 82,200.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,407 shares of the biotechnology company’s stock worth $44,000 after buying an additional 7,398 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in shares of Aclaris Therapeutics by 66.9% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 21,200 shares of the biotechnology company’s stock worth $45,000 after buying an additional 8,500 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Aclaris Therapeutics by 64.1% during the 4th quarter. Legal & General Group Plc now owns 6,495 shares of the biotechnology company’s stock worth $48,000 after buying an additional 2,536 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Aclaris Therapeutics by 199.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 31,246 shares of the biotechnology company’s stock worth $68,000 after buying an additional 20,800 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Aclaris Therapeutics Company Profile (NASDAQ:ACRS)

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Further Reading: How accurate is the Rule of 72?

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.